Tumoural expression of connective tissue growth factor (CTGF) impacts on survival in patients diagnosed with hepatocellular carcinoma (HCC)

Current Cancer Drug Targets

Volumn 15, Issue 5, 2015, Pages 435-444

  Lamarca, Angela ^a,b   Mendiola, Marta ^a   Bernal, Elsa ^a   Heredia, Victoria ^a   Díaz, Esther ^a   Miguel, María ^a   Pastrian, Laura G ^a   Burgos, Emilio ^a   Feliu, Jaime ^a   Barriuso, Jorge ^a,c  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Connective tissue growth factor (CTGF); Hepatocellular carcinoma (HCC); Hypoxia inducible factors (HIF); Survival; Treatment

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR; CTGF PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOPSY; CHRONIC INFLAMMATION; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER FIBROSIS; MALE; OVERALL SURVIVAL; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TUMOR GROWTH; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; SURVIVAL RATE; TRENDS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CONNECTIVE TISSUE GROWTH FACTOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84938686508     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/1568009615666150407124747     Document Type: Article

References (46)

1. [1] Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics. CA Cancer J. Clin., 2013, 63, 11-30.
2. [2] Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics. CA Cancer J. Clin., 2005. 55, 74-108.
3. [3] Llovet, J.M.; Ricci, S.; Mazzaferro, V.; Hilgard, P.; Hilgard, P.; Gane, E.; Blanc, J.F.; de Oliveira, A.C.; Santoro, A.; Raoul, J.L.; Forner, A.; Schwartz, M.; Porta, C.; Zeuzem, S.; Bolondi, L.; Greten, T.F.; Galle, P.R.; Seitz, J.F.; Borbath, I.; Häussinger, D.; Giannaris, T.; Shan, M.; Moscovici, M.; Voliotis, D.; Bruix, J.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 359, 378-390.
4. [4] Cheng, A.L.; Kang, Y.K.; Lin, D.Y.; Park, J.W.; Kudo, M.; Qin, S.; Chung, H.C.; Song, X.; Xu, J.; Poggi, G.; Omata, M.; Pitman Lowenthal, S.; Lanzalone, S.; Yang, L.; Lechuga, M.J.; Raymond, E. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J. Clin. Oncol., 2013, 31, 4067-4075.
5. [5] Jun, J.I.; Lau, L.F. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat. Rev. Drug Discov., 2011, 10, 945-963.
6. [6] Dendooven, A.; Gerritsen, K.G.; Nguyen, T.Q.; Kok, R.J.; Goldschmeding, R. Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers, 2011, 16, 289-301.
7. [7] Capparelli, C.; Whitaker-Menezes, D.; Guido, C.; Balliet, R.; Pestell, T.G.; Howell, A.; Sneddon, S.; Pestell, R.G.; Martinez-Outschoorn, U.; Lisanti, M.P.; Sotgia, F. CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle, 2012, 11, 2272-2284.
8. [8] Urtasun, R.; Latasa, M.U.; Demartis, M.I.; Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology, 2011, 54, 2149-2158.
9. [9] Mazzocca, A.; Fransvea, E.; Dituri, F.; Lupo, L.; Antonaci, S.; Giannelli, G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumorstroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology, 2010, 51, 523-534.
10. [10] Zeng, Z.J.; Yang, L.Y.; Ding, X.; Wang, W. Expressions of cysteine-rich61, connective tissue growth factor and Nov genes in hepatocellular carcinoma and their clinical significance. World J. Gastroenterol., 2004, 10, 3414-3418.
11. [11] Wang, G.B.; Zhou, X.Y.; Yuan, T.; Xie, J.; Guo, L.P.; Gao, N.; Wang, X.Q. Significance of serum connective tissue growth factor in patients with hepatocellular carcinoma and relationship with angiogenesis. World J. Surg., 2010, 34, 2411-2417.
12. [12] Hirasaki, S.; Koide, N.; Ujike, K.; Shinji, T.; Tsuji, T. Expression of Nov, CYR61 and CTGF genes in human hepatocellular carcinoma. Hepatol. Res., 2001, 19, 294-305.
13. [13] Xiang, Z.L.; Zeng, Z.C.; Fan, J.; Tang, Z.Y.; Zeng, H.Y. Expression of connective tissue growth factor and interleukin-11 in intratumoral tissue is associated with poor survival after curative resection of hepatocellular carcinoma. Mol. Biol. Rep., 2012, 39, 6001-6006.
14. [14] Aikawa, T.; Gunn, J.; Spong, S.M.; Klaus, S.J.; Korc, M. Connective tissue growth factor-specific antibody attenuates tumor growth, metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer. Mol. Cancer Ther., 2006, 5, 1108-1116.
15. [15] Dornhofer, N.; Spong, S.; Bennewith, K.; Salim, A.; Klaus, S.; Kambham, N; Wong, C.; Kaper, F.; Sutphin, P.; Nacamuli, R.; Höckel, M.; Le, Q.; Longaker, M.; Yang, G.; Koong, A.; Giaccia, A. Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res., 2006, 66, 5816-5827.
16. [16] Picozzi, V.J.; Pipas, J.M.; Koong, A.; Giaccia, A.; Bahary, N.; Krishnamurthi, S.S.; Lopez, C.D.; O'Dwyer, P.J.; Modelska, K.; Carney, M.; Hernandez, H.; Chou, J.; Lee, T.; Zhong, M.; Porter, S.; Neff, T.; Valone, F.; Seattle, W.A. FG-3019, a human monoclonal antibody to CTGF, with gemcitabine/erlotinib in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma. J. Clin. Oncol., 2012, 30.
17. [17] Charrier, A.; Chen, R.; Kemper, S.; Brigstock, D.R. Regulation of pancreatic inflammation by connective tissue growth factor (CTGF/CCN2). Immunology, 2014, 141, 564-576.
18. [18] Xiu, M.; Liu, Y.H.; Brigstock, D.R.; He, F.H.; Zhang, R.J.; Gao, R.P. Connective tissue growth factor is overexpressed in human hepatocellular carcinoma and promotes cell invasion and growth. World J. Gastroenterol., 2012, 18, 7070-7078.
19. [19] Higgins, D.F.; Biju, M.P.; Akai, Y.; Wutz, A.; Johnson, R.S.; Haase, V.H .Hypoxic induction of Ctgf is directly mediated by Hif-1. Am. J. Physiol. Renal Physiol., 2004, 287, 1223-1232.
20. [20] Haase, V.H. Oxygen regulates epithelial-to-mesenchymal transition: insights into molecular mechanisms and relevance to disease. Kidney Int., 2009, 76, 492-499.
21. [21] Verslype, C.; Rosmorduc, O.; Rougier, P. Hepatocellular carcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2012, 7, 41-48.
22. [22] AJCC Cancer Staging Manual, Seventh Edition, in, 2010.
23. [23] Barriuso, J.; Mariño-Enríquez, A.; Redondo, A.; Domínguez-Cáceres, A.; Hernández-Cortés, G.; Pérez-Fernández, E.; Sánchez-Navarro, I.; Vara, J.A.; Suárez, A.; Espinosa, E.; González-Barón, M.; Palacios, J.; Hardisson, D. Aurora kinases as prognostic biomarkers in ovarian carcinoma. Hum. Pathol., 2009, 40, 631-638.
24. [24] Alvarez, H.; Corvalan, A.; Roa, J.C.; Argani, P.; Murillo, F.; Edwards, J.; Beaty, R.; Feldmann, G.; Hong, S.M.; Mullendore, M.; Roa, I.; Ibañez, L.; Pimentel, F.; Diaz, A.; Riggins, G.J.; Maitra, A. Serial analysis of gene expression identifies connective tissue growth factor expression as a prognostic biomarker in gallbladder cancer. Clin. Cancer Res., 2008, 14, 2631-2638.
25. [25] Li, S.; Yao, D.; Wang, L.; Wu, W.; Qiu, L.; Yao, M.; Yao, N.; Zhang, H.; Yu, D.; Ni, Q. Expression characteristics of hypoxiainducible factor-1alpha and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Hepat., 2011, 11, 821-828, 2011.
26. [26] Yoshimura, H.; Dhar, D.K.; Kohno, H.; Kubota, H.; Fujii, T.; Ueda, S.; Kinugasa, S.; Tachibana, M.; Nagasue, N. Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin. Cancer Res., 2004, 10, 8554-8560.
27. [27] Szabo, G.; Lippai, D. Molecular hepatic carcinogenesis: impact of inflammation. Dig. Dis., 2012, 30, 243-248.
28. [28] Pang, R.W.; Poon, R.T. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology, 2007, 72 (1), 30-44.
29. [29] Marquardt, J.U.; Thorgeirsson, S.S. SnapShot: Hepatocellular carcinoma. Cancer Cell, 2014, 25, 550.
30. [30] Hoshida, Y.; Villanueva, A.; Kobayashi, M.; Peix, J.; Chiang, D.Y.; Camargo, A.; Gupta, S.; Moore, J.; Wrobel, M.J.; Lerner, J.; Reich, M.; Chan, J.A.; Glickman, J.N.; Ikeda, K.; Hashimoto, M.; Watanabe, G.; Daidone, M.G.; Roayaie, S.; Schwartz, M.; Thung, S.; Salvesen, H.B.; Gabriel, S.; Mazzaferro, V.; Bruix, J.; Friedman, S.L.; Kumada, H.; Llovet, J.M.; Golub, T.R. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med., 2008, 359, 1995-2004.
31. [31] Ma, L.; Li, G.; Zhu, H.; Dong, X.; Zhao, D.; Jiang, X.; Li, J.; Qiao, H.; Ni, S.; Sun, X. 2-methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Cancer Lett., 2014, 355(1), 96-105.
32. [32] Lin, Q.; Cong, X.; Yun, Z. Differential hypoxic regulation of hypoxia-inducible factors 1alpha and 2alpha. Mol. Cancer Res., 9, 757-765.
33. [33] Menrad, H.; Werno, C.; Schmid, T.; Copanaki, E.; Deller, T.; Dehne, N.; Brüne, B. Roles of hypoxia-inducible factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of hepatocellular tumor spheroids. Hepatology, 2010, 51, 2183-2192.
34. [34] Xu, W.; Kwon, J.H.; Moon, Y.H.; Kim, Y.B.; Yu, Y.S.; Lee, N.; Choi, K.Y.; Kim, Y.S.; Park, Y.K.; Kim, B.W.; Wang, H.J. Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1alpha pathway in patients with hepatocellular carcinoma. J. Cancer Res. Clin. Oncol., 2014, 140, 1507-1515.
35. [35] Xu, M.; Zheng, Y.L.; Xie, X.Y.; Liang, J.Y.; Pan, F.S.; Zheng, S.G.; Lü, M.D. Sorafenib blocks the HIF-1alpha/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells. DNA Cell Biol., 2014, 33, 275-281.
36. [36] Zhao, D.; Zhai, B.; He, C.; Tan, G.; Jiang, X.; Pan, S.; Dong, X.; Wei, Z.; Ma, L.; Qiao, H.; Jiang, H.; Sun, X. Upregulation of HIF-2alpha induced by sorafenib contributes to the resistance by activating the TGF-alpha/EGFR pathway in hepatocellular carcinoma cells. Cell Signal, 2014, 26, 1030-1039.
37. [37] Wang, W.; Xu, G.L.; Jia, W.D.; Wang, Z.H.; Li, J.S.; Ma, J.L.; Ge, Y.S.; Xie, S.X.; Yu, JH. Expression and correlation of hypoxiainducible factor-1alpha, vascular endothelial growth factor and microvessel density in experimental rat hepatocarcinogenesis. J. Int. Med. Res., 2009, 37: 417-425.
38. [38] Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; Pitot, H.C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton, K.; Chen, S.; Salay, T.M.; Alaparthy, S.; Grosso, J.F.; Korman, A.J.; Parker, S.M.; Agrawal, S.; Goldberg, S.M.; Pardoll, D.M.; Gupta, A.; Wigginton, J.M. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med., 2012, 366, 2455-2465.
39. [39] Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; Leming, P.D.; Spigel, D.R.; Antonia, S.J.; Horn, L.; Drake, C.G.; Pardoll, D.M.; Chen, L.; Sharfman, W.H.; Anders, R.A.; Taube, J.M.; McMiller, T.L.; Xu, H.; Korman, A.J.; Jure-Kunkel, M.; Agrawal, S.; McDonald, D.; Kollia, G.D.; Gupta, A.; Wigginton, J.M.; Sznol, M. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med., 2012, 366, 2443-2454.
40. [40] Rhim, A.D.; Oberstein, P.E.; Thomas, D.H.; Mirek, E.T.; Palermo, C.F.; Sastra, S.A.; Dekleva, E.N.; Saunders, T.; Becerra, C.P.; Tattersall, I.W.; Westphalen, C.B.; Kitajewski, J.; Fernandez-Barrena, M.G.; Fernandez-Zapico, M.E.; Iacobuzio-Donahue, C.; Olive K.P.; Stanger, B.Z. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell, 2014, 25, 735-747.
41. [41] Martinez-Bosch, N.; Fernandez-Barrena, M.G.; Moreno, M.; Ortiz-Zapater, E.; Munné-Collado, J.; Iglesias, M.; André, S.; Gabius, H.J.; Hwang, R.F.; Poirier, F.; Navas, C.; Guerra, C.; Fernández-Zapico, M.E.; Navarro, P. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Res., 2014, 74, 3512-3524.
42. [42] Tsai, H.C.; Su, H.L.; Huang, C.Y.; Fong, Y.C.; Hsu, C.; Tang, C.H. CTGF increases matrix metalloproteinases expression and subsequently promotes tumor metastasis in human osteosarcoma through downregulating miR-519d. Oncotarget, 2014, 5, 3800-3812.
43. [43] Warnke, E.; Pietsch, J.; Wehland, M.; Bauer, J.; Infanger, M.; Görög, M.; Hemmersbach, R.; Braun, M. Ma, X.; Sahana, J.; Grimm, D. Spheroid formation of human thyroid cancer cells under simulated microgravity: a possible role of CTGF and CAV1. Cell Commun. Signal, 2014, 12, 32.
44. [44] Wells, J.E.; Howlett, M.; Cole, C.H.; Kees, U.R. Deregulated expression of connective tissue growth factor (CTGF/CCN2) is linked to poor outcome in human cancer. Int. J. Cancer, 2014, 137(3), 504-511.
45. [45] Kikuchi, R.; Kikuchi, Y.; Tsuda, H.; Maekawa, H.; Kozaki, K.; Imoto, I.; Tamai, S.; Shiotani, A.; Iwaya, K.; Sakamoto, M.; Sekiya, T.; Matsubara, O. The expression and clinical significance of connective tissue growth factor in advanced head and neck squamous cell cancer. Hum Cell, 2014, 27, 121-128.
46. [46] Bota, S.; Piscaglia, F.; Marinelli, S.; Pecorelli, A.; Terzi, E.; Bolondi, L. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma. Liver Cancer, 2012, 1, 190-200.